SCHEMBL3523487

SCHEMBL3523487

COC(=O)CCc1cc2cc(Cl)cc(Cl)c2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.54
PPARA Q07869 11/20 0.54
PPARD Q03181 7/20 0.54
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
ACLY P53396 1/20 0.37
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3523759 0.88 PPARG (0.69) PPARGPPARAPPARDPSEN1PSEN2
SCHEMBL3528397 0.84 PPARG (0.78) PPARGPPARAPPARD
SCHEMBL3525871 0.83 PPARG (0.59) PPARGPPARAPPARDCYP11B1CYP11B2
SCHEMBL3526423 0.81 PPARG (0.69) PPARGPPARAPPARD
SCHEMBL3523098 0.80 PPARG (0.58) PPARGPPARAPPARDCYP11B1CYP11B2
SCHEMBL3524904 0.79 PPARG (0.55) PPARGPPARAPPARDCYP11B1CYP11B2
SCHEMBL3526398 0.78 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL3524660 0.78 PPARG (0.78) PPARGPPARAPPARD
SCHEMBL3523260 0.77 PPARG (0.74) PPARGPPARAPPARD
SCHEMBL3523871 0.77 PPARG (0.67) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARA 847/4885PPARD 677/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.